Gain Therapeutics Inc., a clinical-stage biotechnology company, has announced its intention to offer shares of its common stock and warrants in an underwritten public offering, as detailed in a prospectus filed with the SEC. The company plans to use the proceeds to advance the development of its lead product candidate, GT-02287, aimed at treating neurodegenerative diseases like GBA1 Parkinson's disease. Newbridge Securities Corporation is serving as the sole book-running manager for the offering. The specific terms and timing of the offering will depend on market conditions, and a preliminary prospectus supplement will be made available through the SEC's website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。